Report

Version of Safety Report ID3Safety Report ID10274655primarysourcecountryUSoccurcountryUStransmissiondateformat102transmissiondate26/03/2015reporttype2serious1seriousnesshospitalization1seriousnessother1receivedateformat102Date Received02/07/2014receiptdateformat102Date Last Updated21/07/2014fulfillexpeditecriteria1companynumbUS-ABBVIE-14P-163-1253510-00duplicate1

Report Duplicate

duplicatesourceABBVIEduplicatenumbUS-ABBVIE-14P-163-1253510-00

Primary Source

reportercountryCOUNTRY NOT SPECIFIEDqualification1

Sender

sendertype2senderorganizationFDA-Public Use

Receiver

receivertype6receiverorganizationFDA

Patient

Onset Age27Unit of Onset AgeyearsSexMale

Reaction

1)

reactionmeddraversionpt17.1ReactionRectal perforationOutcomeRecovered/resolved

2)

reactionmeddraversionpt17.1ReactionShockOutcomeRecovering/resolving

3)

reactionmeddraversionpt17.1ReactionPyrexiaOutcomeRecovered/resolved

4)

reactionmeddraversionpt17.1ReactionWeight decreasedOutcomeUnknown

5)

reactionmeddraversionpt17.1ReactionDiarrhoeaOutcomeUnknown

6)

reactionmeddraversionpt17.1ReactionGastrointestinal inflammationOutcomeUnknown

7)

reactionmeddraversionpt17.1ReactionBlood pressure decreasedOutcomeRecovered/resolved

8)

reactionmeddraversionpt17.1ReactionSepsisOutcomeUnknown

9)

reactionmeddraversionpt17.1ReactionCrohn^s diseaseOutcomeNot recovered/not resolved

10)

reactionmeddraversionpt17.1ReactionHeart rate increasedOutcomeRecovered/resolved

11)

reactionmeddraversionpt17.1ReactionAbdominal adhesionsOutcomeUnknown

12)

reactionmeddraversionpt17.1ReactionFistulaOutcomeUnknown

13)

reactionmeddraversionpt17.1ReactionIncreased appetiteOutcomeUnknown

14)

reactionmeddraversionpt17.1ReactionMuscle spasmsOutcomeUnknown

Drug

1)

drugcharacterization2medicinalproductCELEXAdrugindicationPRODUCT USED FOR UNKNOWN INDICATION

activesubstance

activesubstancenameCITALOPRAM HYDROBROMIDE

openFDA Info on Medication

Application NumberNDA020822Brand NameCELEXAGeneric NameCITALOPRAMManufacturersAllergan, Inc.product_ndc0456-4010, 0456-4020, 0456-4040Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsCITALOPRAM HYDROBROMIDERXCUI200371, 213344, 213345, 283672, 284591, 309314spl_iddbff05bb-4557-4d6c-be56-54b239bddae6spl_set_id4259d9b1-de34-43a4-85a8-41dd214e9177Package NDC 0456-4010-01, 0456-4020-01, 0456-4020-11, 0456-4020-63, 0456-4040-01, 0456-4040- ... UNIII1E9D14F36

2)

drugcharacterization2medicinalproductKLONOPINdrugindicationPRODUCT USED FOR UNKNOWN INDICATION

activesubstance

activesubstancenameCLONAZEPAM

openFDA Info on Medication

Application NumberNDA017533Brand NameKLONOPINGeneric NameCLONAZEPAMManufacturersH2-Pharma, LLC, Genentech, Inc.product_ndc61269-605, 61269-610, 61269-620, 0004-0058, 0004-0068, 0004-0098Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsCLONAZEPAMRXCUI197527, 197528, 197529, 206157, 206159, 206160spl_id65d5607d-3926-4b60-97dc-18509af3f271, 0d423291-6115-4522-88db-dcd1096bd432spl_set_idcfa0d79a-843c-4b88-95a1-e9511d649ca1, 542f22e8-dad2-47a8-93b6-30936715d73bPackage NDC 61269-605-10, 61269-610-10, 61269-620-10, 0004-0068-01, 0004-0058-01, 0004-0098- ... NUIN0000175694, M0002356Established Pharmacologic ClassBenzodiazepine [EPC]Chemical StructureBenzodiazepines [CS]UNII5PE9FDE8GB

3)

drugcharacterization1medicinalproductHUMIRAdrugbatchnumbUNKNWONdrugauthorizationnumb125057drugstructuredosagenumb40drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb2drugintervaldosagedefinition803drugdosageformSolution for injection in pre-filled pendrugindicationCROHN^S DISEASEdrugstartdateformat610drugstartdate/02/2014actiondrug4

activesubstance

activesubstancenameADALIMUMAB

openFDA Info on Medication

Application NumberBLA125057Brand NameHUMIRAGeneric NameADALIMUMABManufacturersAbbVie Inc.product_ndc 0074-0067, 0074-3799, 0074-6347, 0074-4339, 0074-9374, 0074-0243, 0074-0554, 007 ... Product TypeHUMAN PRESCRIPTION DRUGRXCUI 351290, 352334, 727703, 727705, 763564, 763565, 797544, 825169, 825170, 1551887, ... spl_id1b259c93-37f5-4845-92ff-224dacfe1d50spl_set_id608d4f0d-b19f-46d3-749a-7159aa5f933dPackage NDC 0074-3799-02, 0074-3799-71, 0074-3799-06, 0074-3799-03, 0074-6347-02, 0074-4339- ...

4)

drugcharacterization2medicinalproductLUNESTAdrugindicationPRODUCT USED FOR UNKNOWN INDICATION

activesubstance

activesubstancenameESZOPICLONE

openFDA Info on Medication

Application NumberNDA021476Brand NameLUNESTAGeneric NameESZOPICLONEManufacturersSunovion Pharmaceuticals Inc.product_ndc63402-190, 63402-191, 63402-193Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsESZOPICLONERXCUI485440, 485442, 485465, 540407, 540409, 540411spl_id4c2704d7-3027-4240-9073-3f0b24cf15b5spl_set_idfd047b2b-05a6-4d99-95cb-955f14bf329fPackage NDC 63402-190-30, 63402-191-03, 63402-191-10, 63402-191-01, 63402-191-30, 63402-193- ... UNIIUZX80K71OE

summary

narrativeincludeclinicalCASE EVENT DATE: 201402

Adverse Event Report

Report

Report Duplicate

Primary Source

Sender

Receiver

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

8)

9)

10)

11)

12)

13)

14)

Drug

1)

activesubstance

openFDA Info on Medication

2)

activesubstance

openFDA Info on Medication

3)

activesubstance

openFDA Info on Medication

4)

activesubstance

openFDA Info on Medication

summary

Media

Newsletter

Follow us

Connect with us